دورية أكاديمية
Metastatic primary breast neuroendocrine neoplasms: a case series.
| العنوان: | Metastatic primary breast neuroendocrine neoplasms: a case series. |
|---|---|
| المؤلفون: | Batty K; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Taylor AM; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Bernard EJ; Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia., Diakos CI; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia., Clarke SJ; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia., Guminski A; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Baron-Hay S; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Boyle F; Patricia Ritchie Centre for Breast Cancer Research, Mater Hospital, North Sydney and University of Sydney, The Mater Hospital, Sydney, New South Wales, Australia.; University of Sydney, Sydney, Australia., Pavlakis N; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia., Chan DL; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia. |
| المصدر: | Internal medicine journal [Intern Med J] 2023 Oct; Vol. 53 (10), pp. 1813-1818. Date of Electronic Publication: 2022 Oct 31. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 101092952 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1445-5994 (Electronic) Linking ISSN: 14440903 NLM ISO Abbreviation: Intern Med J Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Carlton, Vic. : Blackwell Science Asia, c2001- |
| مواضيع طبية MeSH: | Neuroendocrine Tumors*/diagnostic imaging , Neuroendocrine Tumors*/therapy , Breast Neoplasms*/diagnostic imaging , Breast Neoplasms*/therapy , Carcinoma, Neuroendocrine*/diagnostic imaging , Carcinoma, Neuroendocrine*/therapy , Neoplasms, Second Primary*, Humans ; Female ; Adult ; Middle Aged ; Prognosis ; Fluorodeoxyglucose F18 ; Retrospective Studies |
| مستخلص: | Background: Breast neuroendocrine neoplasms represent a rare subtype of breast cancer which have not been well studied or characterised, particularly in the metastatic setting. Aim: To present clinicopathological characteristics, treatment and outcomes of a series of patients with metastatic neuroendocrine carcinoma of the breast and review the current literature. Methods: We performed a retrospective review to identify and describe patients with metastatic neuroendocrine carcinoma of the breast at our centre between 2011 and 2021. Medical records, pathology and imaging results were examined to evaluate the clinical and histopathological features as well as the treatment pathways and prognosis of these patients. Results: We present a series of seven female patients with metastatic neuroendocrine carcinoma of the breast, as defined by the World Health Organization classification, over a period of 10 years (2011-2021) from a single centre. Median age at diagnosis was 48 years (range 39-63). Six of seven tissue samples expressed synaptophysin and chromogranin and were also oestrogen and progesterone receptor positive; median Ki-67 index was 50% (range 20-90%). All seven patients had demonstrated avidity on 18 F-FDG PET imaging, and the six who underwent 68 Ga-DOTATATE PET all had significant avidity. Treatment modalities and sequencing varied, but all patients received chemotherapy during their disease course. Six patients received three or more lines of treatment. Median overall survival was 31.8 months (range 3.7-108.6). Median progression-free survival (PFS) with first-line therapy for metastatic disease was 5.8 months (range 1.8-37.8). Conclusions: This series shows the use of multiple modalities in treating this disease, with different sequencing in different patients. Despite multiple modalities used in the first-line setting, first-line PFS remains short. Larger series and further molecular characterisation are required to aid clinicians in managing this condition and to guide optimal treatment sequencing to improve outcomes in this rare patient group. (© 2022 Royal Australasian College of Physicians.) |
| References: | Tsang JY, Tse GM. Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. Mod Pathol 2021; 34: 1062-73. Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology 2020; 77: 181-5. Bussolati G, Badve S. Carcinomas with neuroendocrine features. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH and van de Vijver MJ, eds World Health Organization Classification of Tumours of the Breast, 4th edn. Lyon: IARC Press; 2012; 62-3. Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Mod Pathol 2018; 31: 68-82. Vranic S, Palazzo J, Sanati S, Florento E, Contreras E, Xiu J et al. Potential novel therapy targets in neuroendocrine carcinomas of the breast. Clin Breast Cancer 2019; 19: 131-6. Jurčić P, Krušlin B, Gatalica Z, Sanati S, Vranic S. Breast carcinoma with neuroendocrine features: a brief review. Endocr Oncol Metabol 2016; 2: 138-45. Rosen L, Gattuso P. Neuroendocrine tumor of breast. Arch Pathol Lab Med 2017; 141: 1577-81. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH et al. Metastatic behaviour of breast cancer subtypes. J Clin Oncol 2010; 28: 3271-7. Chan DLH, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A et al. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics 2017; 7: 1149-58. Hofman M, Hicks R. Changing paradigms with molecular imaging of neuroendocrine tumours. Discov Med 2012; 14: 71-81. Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B et al. Prognostic value of intrinsic subtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatinib. JAMA Oncol 2016; 2: 1287-94. Strosberg J, Nasir A, Coppola D, Wick M, Kvols L. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumours. Hum Pathol 2009; 40: 1262-8. Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017; 189: E398-404. Inno A, Bogina G, Turazza M, Bortesi L, Duranti S, Massocco A et al. Neuroendocrine carcinoma of the breast: current evidence and future perspectives. Oncologist 2016; 21: 28-32. Irelli A, Sirufo MM, Morelli L, D'Ugo C, Ginaldi L, De Martinis M. Neuroendocrine cancer of the breast: a rare entity. J Clin Oncol 2020; 9: 1452. Buttar A, Mittal K, Khan A, Bathini V. Effective role of hormonal therapy in metastatic primary neuroendocrine breast carcinoma. Clin Breast Cancer 2011; 11: 342-5. Magi L, Mazzuca F, Rinzivillo M, Arrivi G, Pilozzi E, Prosperi D et al. Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center. J Clin Med 2019; 8: 910. |
| فهرسة مساهمة: | Keywords: breast carcinoma; breast neoplasms; cancer of the breast; malignant neoplasm; neuroendocrine tumour |
| المشرفين على المادة: | 0Z5B2CJX4D (Fluorodeoxyglucose F18) |
| تواريخ الأحداث: | Date Created: 20221031 Date Completed: 20231023 Latest Revision: 20231120 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1111/imj.15961 |
| PMID: | 36314732 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1445-5994 |
|---|---|
| DOI: | 10.1111/imj.15961 |